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Abstract: The diagnosis of cow’s milk allergy (CMA) is particularly challenging in infants, especially
with non-Immunoglobulin E (IgE)-mediated manifestations, and inaccurate diagnosis may lead
to unnecessary dietary restrictions. The aim of this study was to assess the accuracy of the
cow’s milk-related symptom score (CoMiSSTM) in response to a cow’s milk-free diet (CMFD).
We prospectively recruited 47 infants (median age three months) who had been placed on a CMFD
due to persisting unexplained gastrointestinal symptoms. We compared data with 94 healthy controls
(median age three months). The CoMiSSTM score was completed at recruitment and while on the
exclusion diet. In 19/47 (40%) cases a response to the diet occurred. At recruitment CoMiSSTM was
significantly higher in cases compared to controls (median score 8 vs. 3; p-value: <0.05), 9 cases
had a score ≥12 and 8/9 normalized on CMFD. An oral milk challenge was performed in all 19
responders and six of these had a positive reaction to cow’s milk (CM). In eight infants IgE allergy
tests were positive. The receiver operation characteristic (ROC) curve identified a CoMISSTM score of
9 to be the best cut-off value (84% sensitivity, 85% specificity, 80% positive (PPV) and 88% negative
predictive value (NPV)) for the response to CMFD. We found CoMiSSTM to be a useful tool to help
identify infants with persisting gastrointestinal symptoms and suspected CMA that would benefit
from CMFD.
Keywords: cow’s milk allergy; regurgitation; CoMiSSTM; cow’s milk-free diet; infants; crying;
hydrolysed formulas; gastrointestinal
1. Introduction
Cow’s milk (CM) protein allergy (CMA) is an immune reaction to specific CM proteins occurring
in 2–5% of infants, presenting with skin, gastrointestinal (GI) and/or respiratory symptoms [1,2].
These manifestations can be acute, and in rare cases even life threatening, such as anaphylaxis, or can
be chronic. In infants with gastrointestinal symptoms, the diagnosis of CMA is particularly challenging
due to the lack of optimal diagnostic tests, lack of biomarkers and a broad spectrum of presenting
symptoms [3–5]. Several risk factors have been identified for CMA, but its pathogenesis and clinical
correlation still needs to be fully clarified for both breast- and formula-fed infants [6–9]. A cow’s
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milk-free diet (CMFD) is a recognized treatment option for infants with diagnosed CMA [1,2,5,10].
However, not all GI symptoms are allergic in nature. Regurgitation, excessive crying or colic,
for example, are common physiological conditions, often showing spontaneous resolution in the first
months of life. An oral food challenge (OFC) is considered necessary to confirm the diagnosis of CMA
as well as the acquisition of tolerance [1,2,5,10]. However, it is often difficult to interpret, particularly in
children with non-IgE-mediated CMA, which may take days or weeks to diagnose, or may be refused
by parents who fear severe reactions [5,10,11].
For these reasons, different nutritional and pharmacological tests have been employed to try
to improve the diagnosis [4,10,12,13]. The real challenge for the clinician is how to rapidly identify
subjects who may benefit from CMFD when CMA is suspected. In 2015 a Belgian group created a
symptom-based score system [14] to help in the identification of infants with CMA, especially those
with non-IgE mediated forms. Crying, regurgitation, stool pattern, skin and respiratory symptoms
were all considered, and an arbitrary cut-off of 12 points was suggested as a possible score to indicate
CMA [14]. The authors introduced the acronym “CoMiSSTM” (cow’s milk-related symptom score
awareness tool) [15]. The score was assessed in symptomatic infants (aged two weeks to six months) at
initial diagnosis of CMA, and later when placed on the CMFD [15]. OFC was positive in 80% of infants
in which CoMiSSTM decreased to ≤6 after one month of elimination diet [15]. Since then, four other
reports confirmed the high predictive value of CoMiSSTM in relation to the CM OFC; the reduction of
the score to <6 was also associated with the response to CMFD [16–19]. Very recently, an international
study tested the score in a population of healthy infants and found a median value of 3 [20].
We aimed to assess the accuracy of CoMiSSTM in identifying infants with gastrointestinal symptoms
who benefit from CMFD.
2. Methods
2.1. Design of the Study
This was an open prospective study assessing CoMiSSTM in infants (aged between 1 and 12 months)
who started CMFD due to acute or chronic symptoms or gastrointestinal symptoms suspected for CMA.
CoMiSSTM is a simple tool that rates five different symptoms: Daily duration of crying, number
and volume of episodes of regurgitation, consistency of stools, presence and severity of atopic eczema
or urticaria and presence and severity of respiratory symptoms (supplementary File S1). CoMiSSTM
ranges from 0 to 33 points: Crying, regurgitation and cutaneous symptoms are scored from 0 to 6,
with each increase of 1 point meaning more severe symptoms, up to 6 points as the worst symptom;
respiratory symptoms are scored from 0 to 3, with 0 as no symptom, 1 mild, 2 moderate and 3 severe.
Stool consistency is scored based on the Bristol stool scale with 0 for normal stools (type 3 and 4),
2 points for soft stools (type 5), 4 points for hard stools (type 1 and 2) or liquid stools (type 6) and
6 points for watery stools (type 7).
The primary outcome is to establish the sensitivity and specificity of CoMiSSTM in identifying
infants who respond to CMFD. The secondary outcomes include the evaluation of the score in healthy
infants and to identify the best cut-off score in the symptomatic population.
This was an independent study in all stages of the design and conduction, collection, management,
analysis or interpretation of the data, preparation, review and approval of the paper. We downloaded
the CoMiSSTM tool from the dedicated website.
All parents of enrolled infants signed a written consent and the study was approved by our
Institutional Review Board.
2.2. Study Population
From October 2017 to June 2018 we recruited infants referred to our pediatric gastroenterology
clinic who had started a CMFD due to persistent unexplained gastrointestinal symptoms (such as
vomiting, regurgitation, constipation or diarrhea) and/or other manifestations (such as failure to
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thrive, crying/fussiness, sleeping problems, dermatitis and feeding refusal). Infants presenting with
unequivocal and/or severe acute symptoms after introduction of CM protein who also had positive IgE
test results were prescribed a CMFD. In all other infants, parental reassurance, behavior management
and nutritional advice (adequate intake and thickening formulas in regurgitating infants) were first
attempted for at least one week. CMFD was started if a clear improvement, as perceived by parents,
did not occur. Infants were excluded if they were older than 12 months of age, already on CMFD,
on enteral tube feeding, neurologically impaired, had gastrointestinal malformations or surgery or
were on anti-reflux medication.
2.3. CoMiSSTM Evaluation
Based on the infant’s clinical history, CMFD was introduced by an expert pediatric
gastroenterologist (SS) blind to the CoMiSSTM. The score was completed by another clinician
helping parents of recruited infants at the first clinical evaluation (T0) after 2–4 weeks of diet (T1) and,
eventually, after oral challenge (T2). Age, gender, dietary intake, results of allergy tests and family
history of allergy were also recorded.
We defined a positive score when CoMiSSTM was ≥12 (as originally proposed [14]) and a negative
score when it was <12. Based on parents’ reports, we calculated any variation of the score on diet and
the number of infants who switched from a positive to a negative CoMiSSTM. We also compared the
CoMiSSTM score of symptomatic infants with the score obtained (only at enrollment, T0) in a control
group of infants referred for a minor trauma, not on diet or on anti-reflux medication and perceived
by parents as healthy infants. To limit the possible effect of physiologic improvement of symptoms
with time we created a mathematical model to rate the response to CMFD that was defined as having
a score that decreased by least 50% from T0 and below the median value of the control population.
To limit a possible false negative result from the CoMiSSTM we analyzed also infants who had had a
negative score at first visit.
2.4. CMFD
In formula-fed infants, hypoallergenic formulae were used for the management of CMA, while in
breast-fed infants, maternal CMFD was recommended and continuation of breast-feeding. In this
study infants on exclusive formula-feeding were prescribed either an amino acid formula (AAF),
an extensively hydrolysed formula (eHF) or a rice-based hydrolysate formula (RHF). In infants already
weaned, CM protein was excluded from their complementary feeds.
2.5. Allergy Tests and OFC
In all infants who commenced on the CMFD, allergy tests were performed and an open food
challenge took place within three months following inclusion. Skin prick tests were performed on the
infant’s volar forearm using a 1-mm disposable lancet, a standard CM-based formula (prick to prick
test) as well as histamine, a saline solution (negative control) and CM-protein allergens manufactured
by ALK, Copenhagen, Denmark. After 15 min the maximal diameter of the wheal and flare were
recorded. A positive skin prick test result was considered when the diameter of the wheal was larger
than 3 mm compared to the negative (saline) control.
The open CM challenge was performed in our hospital according to the previous consensus
report [21] and guidelines [5,10] and was interpreted by two experienced clinicians (MM and CL)
who were blinded to the study and to the CoMiSSTM score. For the OFC, the protocol was based on
semi-logarithmic incremental doses of CM protein (3, 10, 30, 100, 300, 1000 and 3000 mg) at intervals
of 20 min [21]. The infant was observed for an additional 2 h in the hospital after the last dose was
administered, while being monitored for any reaction. Acute reactions were defined as those occurring
within 2 h of the last dose of CM during the challenge. In the absence of an acute reaction, the parents
were instructed to give the infant at least 250 mL per day of a standard CM-protein based formula at
home, starting the following morning for 14 days [16]. During this period parents continued to monitor
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symptoms, informing the clinician in cases of occurrence of symptoms including gastrointestinal,
cutaneous, respiratory or general. Delayed reactions were considered up to 2 weeks from the OFC
in the absence of other possible confounding effects (i.e., infection). A positive OFC was considered
when at least one of the following symptoms occurred: Urticaria (>3 hives), severe lip or face edema,
generalized erythema, persistent sneezing or rhinorrhea or dry cough, hoarseness, wheezing or stridor,
at least two episodes of vomiting or loose stools, altered mental status /hyporeactivity or cardiovascular
collapse [21].
2.6. Statistical Analysis
Demographic data, symptoms, CoMiSSTM scores, results of the allergy tests and of the OFC, the
type of CMFD and family history of allergy were all recorded in an Excel database. An independent
statistician performed the statistical analysis by R program (RStudio Version 1.0.136—© 2009–2016,
RStudio, Inc., Boston, MA, US). Median values were considered whenever a non-normal distribution
was present.
We compared the CoMiSSTM distribution and the median score at enrollment in cases and controls
(T0) and when off and on CMFD in cases (T1).
For statistical evaluation, responsive to CMFD’ was defined as all infants who passed from a
CoMiSSTM score above the median of the symptomatic population at T0 to a score below the median
of the control population at T1. We also studied the normalization of the score, i.e., the transition of
CoMiSSTM from T0 ≥12 to T1 <12.
We used the Wilcoxon test as non-parametric statistical test and we analyzed the CoMiSSTM score
at T0 and T1; significance was set at p value <0.05. We calculated the sensitivity, specificity and positive
(PPV) and negative predictive value (NPV) and created a ROC-curve to identify the best cut-off for
CoMiSSTM to predict the response to CMFD.
The sample size calculation was based on a previous study where CoMiSSTM was used to assess
symptoms in infants with CMA who had been prescribed an extensively hydrolyzed formula. In this
study 29 infants were included [16]. As healthy infants were evaluated just once and symptomatic
infants at least twice, we arbitrarily fixed that the number of the control population should double the
number of cases.
3. Results
We recruited 47 infants who had commenced on a CMFD (26 male, median age 3 month, range
10 days–8 months) and 94 healthy controls (43 male, median age 3 months, range 15 days–8 months).
At recruitment (T0) the median score of CoMiSSTM was 8 (range 2–16) in cases and 3 (range 0–11)
in controls.
3.1. CoMiSSTM Evaluation
In the control group the vast majority of the population had a score <6, 34% between 0 and 1 and
45% of controls between 2 and 6. The score was significantly lower than in the CMA group (p < 0.05).
The distribution of the CoMiSSTM score at T0 in cases and controls is shown in Figures 1 and 2.
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Table 1. Comparison of CoMiSSTM items and scores between cases and controls.
Crying Regurgitation Stools (Bristol Scale) * Skin Symptoms Respiratory Symptoms
Group CasesN (%)
Controls
N (%) p
Cases
N (%)
Controls
N (%) P
Cases
N (%)
Controls
N (%) P
Cases
N (%)
Controls
N (%) P
Cases
N (%)
Controls
N (%) P
YES 35 (75) 52 (55)
N.S.
35 (75) 57 (61)
N.S.
20 (43) 35 (37)
N.S.
18 (38) 14 (15)
0.04
20 (43) 18 (19)
N.S.
NO 12 (25) 42 (45) 12 (25) 37 (39) 27 (57) 59 63) 29 (62) 80 (85) 27 (57) 76 (81)
TOTAL 47(100) 94 (100) - 47(100) 94(100) - 47(100) 94(100) - 47(100) 94(100) - 47(100) 94(100) -
Score
0 12 (26) 42 (45) N.S. 12 (26) 37 (39) N.S. 27 (57) 59 (63) N.S. 29 (62) 80 (85) 0.04 27 (57) 76 (81) N.S.
1 5 (11) 25 (27) N.S. 8 (17) 30 (32) N.S. n.a. n.a. n.a. 5 (11) 6 (6) N.S. 12 (26) 13 (14) N.S.
2 9 (19) 17 (18) N.S. 11 (23) 17 (18) N.S. 5 (11) 28 (30) N.S. 4 (8) 6 (6) N.S. 8 (17) 4 (4) N.S.
3 8 (17) 9 (10) N.S. 4 (8) 10 (11) N.S. n.a. n.a. n.a. 1 (2) 0 N.S. 0 1 (1) N.S.
4 7 (15) 1 (1) 0.02 5 (11) 0 0.03 15 (32) 7 (7) 0.01 2 (4) 2 (2) N.S. n.a. n.a. n.a.
5 3 (6) 0 N.S. 2 (4) 0 N.S. n.a. n.a. n.a. 0 0 - n.a. n.a. n.a.
6 3 (6) 0 N.S. 5 (11) 0 0.03 0 0 - 6 (13) 0 0.01 n.a. n.a. n.a.
Legend: N = number of infants; % = percentage; YES was considered when the symptom was reported; * for Stools YES was considered when Bristol Scale was , 0; N.S. was considered
when p > 0.05; n.a.: Not applicable because the CoMiSSTM does not include this point score for this item in the Bristol scale or in the respiratory symptoms.
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3.2. Clinical Presentation
In our population the most frequent symptoms were crying and regurgitation both reported in
75% of cases. Unexplained rectal bleeding was reported in four infants (8%) and was associated with
other symptoms.
Seven (15%) infants had symptoms such as vomiting and/or urticaria that occurred acutely after
CM protein exposure, but none had anaphylaxis or required adrenalin. CoMiSSTM was not significantly
different (p = 0.31) in infants with acute or chronic symptoms (median 8 vs. 7.5, range 6–13 vs. 2–15).
Parents reported a reduction of symptoms in infants on the CMFD in 39 (83%) of cases; 19 (40%)
had a significant response to CMFD as defined above. The decrease of the CoMiSSTM score in cases
after 2–4 weeks of cow‘s milk-free diet (CMFD) is shown in Figure 3.
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Differences between responders and non-responders to CMFD are reported in Table 2.
Table 2. Comparison between infants with response or no response to CMFD.
RESPONSE to CMFD NO RESPONSE to CMFD p-Value
N (%) N (%)
Number of cases 19 (40) 28 (60) N.S.
Median age at enrollment 3 mo 3 mo N.S.
Family history of allergy 14 (74) 10 (36) 0.02
Positive SPT 5 (26) 3 (11) N.S.
Breast Milk (BM)
Exclusive BM
BM + formula
BM +complementary feeding
5
3
0
2
(26)
(16)
(0)
(10)
6
4
0
2
(21)
(14)
(0)
(7)
N.S.
N.S.
-
N.S.
Formula Fed
- AAF
- eHF
- RiceHF
14
2
10
2
(74)
(10)
(53)
(10)
22
3
19
0
(79)
(11)
(68)
(0)
N.S.
N.S.
N.S.
N.S.
Median CoMiSS at T0 10 5.5 0.01
CoMiSS ≥12 at T0 7 (37) 2 (7) 0.03
Symptoms median score mean score ± SD median score mean score ± SD
cry 2 2.7 ± 1.9 2 2.1 ±1.9 N.S.
regurgitation 2 2.3 ± 1.9 2 1.8 ± 1.9 N.S.
stools 0 2.6 ± 1.9 0 0.78 ± 1.8 N.S.
skin symptoms 0 2.4 ± 2.2 0 0.6 ±2.2 N.S.
respiratory symptoms 0 0.6 ± 0.7 0 0.6 ± 0.78 N.S.
Acute symptoms 4 (21) 3 (11) N.S.
Chronic symptoms 15 (79) 25 (89) N.S.
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The median score of CoMiSSTM was significantly higher in infants who responded to the diet
compared to the ones who did not respond (see Figure 4).
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Figure 4. Box plot distribution of CoMiSSTM at baseline comparing infants who responded and did not
respond to CMFD.
Only nine of the 47 infants (19%) who started CMFD had a CoMiSSTM score ≥12 at T0, and eight
out of nine (89%) had a negative (<12) score at T1. One infant who did not achieve a negative score
at T1 was subs quently diag o ed with gastroesophageal reflux disease, based on a pathological
impeda ce-pH monitoring, which improved on acid inh bitors.
3.3. Diet
The majority of infants on CMFD were prescribed an extensively hydrolyzed CM protein formula
(29/47, 62%). 11% (five infants) were taking an amino acid-based formula due to more severe
or acute reactions and 10% (two infants) of infants were taking a rice-based hydrolyzed formula.
A maternal diet was started in seven infants, exclusively breast-fed (7/47, 15%), and was associated to
CM protein exclusion in four breast-fed infants already having complementary feeding. At T1 the
median CoMiSSTM decreased more in infants on amino acid-based formulas compared to the ones on
extensively hydrolyzed formulas (−8.5 points vs. −4.5 points).
Eight infants (17%) showed positive allergy tests to CM proteins. Among the 39 infants whose
parents reported an improvement of symptoms on CMFD, OFC was performed in 21 infants (54%),
and in all the 19 infants who showed a statistical response to CMFD, as defined above. The OFC was
carried our after 2–10 ( ean 6 ± 4.2) months from starting the elimination diet: Three patients had
acute reactions and three reported the recurrence of symptoms in the following days. The other 15/21
(71%) infants had negative OFC. The median age at OFC was 9 months (SD ± 4 months).
3.4. Family History
Family history of allergy was reported in 24/47 (51%) infants and the median CoMiSSTM in this
group did not differ from the one obtained in the 23 infants with a negative family history (8.5 vs. 7,
p = 0.35). However, family history of allergy significantly influenced the response to CMFD; 14 of the
19 responsive infants (74%) had a family history of allergy compared to 10 of the 28 infants (36%) who
did not respond (p = 0.02).
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3.5. CoMiSSTM Cut-off
Only 7/19 of the infants who responded to CMFD (37%) had a T0 CoMiSSTM score ≥12, and the
other 12 infants (63%) had a T0 CoMiSSTM score <12. Only two of the infants who did not respond to
the diet had a T0 CoMiSSTM score ≥12. Applying the cut-off score of 12 we obtained a sensitivity of
0.37 (7/19) and a specificity of 0.92 (26/28); the PPV was 0.77 (7/9) and the NPV was 0.68 (26/38).
The ROC curve identified the score of 9 as the best cut-off for the test (area under the curve 0.91):
91% of the real positive infants (responsive to CMFD infants with a positive test) showed a significantly
higher score than the real negative non-responsive infants (see Figure 5).
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Figure 5. ROC curve of the CoMiSSTM score.
The sensitivity of the test with a cut-off of 9 was 0.84 (16/19), and the specificity 0.85 (24/28),
the positive predictive value (PPV) was 0.8 (16/20) and the negative predictive value (NPV) was
0.88 (24/27).
4. Discussion
In our population of infants referred to the GI clinic with persistent GI symptoms suspected to be
related to CMA, a p sitive CoMiSSTM score appeared to predict thos infants who later respon ed
to CMFD. A score of 9 could better predict those who would respond to the CMFD inst ad of 12,
as previously suggested. The CoMiSSTM score was significantly different between case an control
and between those off or on MFD. ost infant who benefited from CMFD showed more tha one
symptom, wi crying and regurgitati n being the most frequently reported but neithe necessary
nor sufficient o p edict the response to the limination diet. Th group of infants who r sponded to
the CMFD with a uction of C MiSSTM below the me ian of the contr l population include both
infants with IgE positive and negative test r sults and also breast-fed infants.
The diagnosis of CMA in infan s is often challenging, particul rly in cases with chronic
gastrointestinal symptoms and negative allergy tests [1–5,10]. No symptom or sign alone is specifi
for he diagnosis of CMA or predictive of a respon e to CMFD [4,5,10,11]. Clinical presentation may
overlap with functional gast ointestinal disorders, gastroesophageal reflux disease, inf ctions or other
conditions [4,12,22,23]. OFC is co sidered the gold standard method to diagnose CMA [1,2,5,10], but it
is often refused by parents of young infant or delayed due to fear of a severe reaction or for other
reasons. Hence, when OFC is performed the in ants could have natur lly resolved their symptoms
through and acquir d CM tolerance. Furthermore, the clinical reactio during or after a OFC is
sometimes d fficult to interp et, especially in infants, and is possibly related to mechanisms other
than immune activation [4,11,22–24]. Protein hydr lysis acc lerates g stric emptying time, im roving
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motility or gastroesophageal-related symptoms [4,11,12,23]. In addition, the absence or reduction of
lactose content may reduce intestinal gas, the fermentation process, crying and diarrhea in a subgroup
of patients [4,12]. As a result, in infants with gastrointestinal symptoms, CMA may be over-diagnosed
and CMFD unnecessarily prolonged [23,24]. Nevertheless, acid inhibitors are often inappropriately
started for symptoms that could improve on CMFD [12]. For these reasons, it is necessary to find a
handy clinical tool that identifies infants who can benefit from a CMFD, and that can monitor the
efficacy of the elimination diet [24].
CoMiSSTM has recently been introduced as an “awareness tool” for CM-related symptoms [14,15].
In the last years different authors reported a good correlation between a positive (score ≥12) CoMiSSTM
and a positive OFC and showed a reduction of the score on CMFD [16–19]. Very recently, an international
study tested the specificity of CoMiSSTM in a population of healthy infants and found a median value
of 3 [20].
We found the same median score using CoMiSSTM in our healthy control group, with none of
these healthy infants scoring above 11. Different from previous studies, we also included symptomatic
infants with a negative CoMiSSTM. In our population, the ROC curve identified the cut-off of 9 as the
most accurate score, with a significant increased sensitivity and negative predictive value, a similar
positive predictive value and a just slightly reduced specificity of the test compared to the cut-off of
12 (from 92% to 85%).
The main strength of our study was that we compared the CoMiSSTM score in a group of
symptomatic infants with a group of healthy age matched controls. In addition, we could analyze
the accuracy of the score in a group of infants with prevalent non-IgE manifestations before and
during CMFD and, in the ones who benefited from the diet, also after the challenge. We also collected
additional symptoms possibly related to CMA such as rectal bleeding [22] and feeding and sleeping
problems. However, we did not find any significant correlation, possibly due to the limited number
of patients.
Family history of allergy did not influence the clinical presentation in our cohort but was
significantly more common in infants who responded to CMFD. The major limitation of this study
was due to its open design, with the CoMiSSTM scored based on parental reporting and with the
performance of an open OFC only in some patients. To reduce these potential flaws both the clinician
who prescribed the CMFD and the clinician who interpreted the OFC were unaware (blind) of
the CoMiSSTM score. However, we could not exclude a placebo effect of CMFD or a physiologic
improvement of symptoms with the progression of time. To limit these effects we compared the
CoMiSSTM score in symptomatic infants with the CoMiSSTM score of healthy infants. In addition
we constructed a mathematical model to rate a (significant) response to CMFD at a score value of 2,
lower than the median score of our control population. This score was largely below the positive
CoMiSSTM score of 12 and the cut-off reduction of <6, as originally proposed. Forty per cent of our
population significantly responded to CMFD and different types of elimination diet were well tolerated
and continued despite the palatability, considered poor, of the extensive hydrolyzed and the amino
acid-based formulas [25]. However, OFC was performed only in half of the enrolled population and,
in most cases, delayed beyond the scheduled time, which may have impacted our results. OFC was
positive in 29% of infants who responded to CMFD, which might suggest that tolerance was already
acquired, or the CMFC was unnecessary and prolonged. As we only followed up on the symptomatic
infants on CMFD we could analyze neither the possible placebo effect of the elimination diet nor the
natural evolution of the reported symptoms. However, for ethical, medical and economic reasons,
a CMFD and a subsequent OFC could not be proposed to healthy infants without marked or persistent
gastrointestinal symptoms. Our group of patients was also heterogeneous in terms of CMFD with
11/47 (23%) being breast-fed. The small sample size did not allow us to analyze the different types of
diet or to generalize our results for infants with different clinical presentations. Moreover, we did not
consider ethnicity, psychosocial and economical factors all of which may influence the parental report
of symptoms and CoMiSSTM results.
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To date, in infants with chronic symptoms and negative allergy tests, CMFD is often started
based on a subjective interpretation of clinical history and clinicians‘ attitudes and experience [24].
If our results will be be confirmed in a larger population, CoMiSSTM could be introduced into clinical
practice as a valuable tool for thedetection of infants with GI symptoms who should start CMFD and
could be used to monitor these infants during their period of CM exclusion, and possibly during the
reintroduction of CM protein.
The improvement of symptoms with targeted dietary treatment could also reduce the stress level
of caregivers and the healthcare costs and improve the quality of life of food-allergic infants and
family [12,13,24].
5. Conclusions
CoMiSSTM can be a helpful tool to identify which infants with persisting gastrointestinal symptoms
would benefit from CMFD when CMA is suspected. Our findings support the use of CoMiSSTM in
both IgE positive and negative infants; we propose a lower cut-off score of 9 to improve the accuracy
of the test. However, our results need validation by other groups before routine use of CoMiSSTM is
recommended in clinical practice.
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